Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

When they came up with “Common Side Effects,” Bennett recalled in a recent interview, he was thinking about their prominence ...

Indian pharmaceutical companies lag behind global peers in ESG practices, facing regulatory, awareness, and resource ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Dear reader, China’s biotechnology sector has rapidly emerged as one of the fastest-growing industries, with Chinese players ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years ...

Nirmala Sitharaman proposed several changes to basic customs duties, including exemptions for life-saving medicines and ...

Finance Minister Nirmala Sitharaman's budget announcement on medical tourism praised by industry leaders for boosting India's healthcare sector.

Summary: The Union Budget 2025 proposes a rationalized customs tariff structure by removing seven tariff rates, leaving only eight, with minor reductions on select items. To support domestic ...